Biotech news, week of July 6, 2026

Monday, July 6, 2026

1. 0122:10 UTC

   Moderna, Revolution Medicines, Axsome beat S&P 500 in first half, Motley Fool reports

   2 outlets · first: fool.com

   Machine summary The Motley Fool reported that, in the first six months of 2026, Moderna, Axsome Therapeutics and Revolution Medicines beat the S&P 500.

   1. The Motley Fool reported that Moderna, Revolution Medicines and Axsome Therapeutics surpassed the S&P 500's gain of more than 9% in the first half of 2026.
   2. According to the report, Moderna intends to introduce up to three new products by the end of 2028.

   Reported by fool.com and nasdaq.com.

   • Moderna
   • Revolution Medicines
   • Axsome Therapeutics

2. 0223:00 UTC

   Colorado attorney general announces $12 million in opioid prevention grants

   1 outlet · first: kjct8.com Funding

   Machine summary kjct8.com reported that Colorado Attorney General Phil Weiser announced $12 million in grants for 27 organizations to expand opioid prevention programs, with the aim of investing opioid settlement funds in substance-use prevention. The report said the Department of Law got 287 applications seeking more than $171 million, and that the chosen projects will serve every region of Colorado. It also said the grants are

   1. The grants aim to invest opioid settlement funds into programs preventing substance use, KKTV reported.

   Reported by kjct8.com.

Tuesday, July 7, 2026

5 events. The full rundown for July 7, 2026. The most covered:

1. 17:00 UTC WHO says first patients enrolled in Bundibugyo Ebola drug trial 7
2. 12:15 UTC Planned Parenthood resumes Medicaid billing after funding restored 3
3. 04:45 UTC Bayer Foundation award honours 15 women entrepreneurs 2

Wednesday, July 8, 2026

6 events. The full rundown for July 8, 2026. The most covered:

1. 20:15 UTC orlandosentinel.com: “Michigan battles largest cyclospora outbreak in state history” 6
2. 22:30 UTC Judge orders 23andMe to pay $46.75 million breach settlement 3
3. 03:30 UTC dsm-firmenich Awards €250K for 5 Longevity Research Projects Targeting Asia Pacific Aging 2

Thursday, July 9, 2026

1. 0301:45 UTC

   HanchorBio Broadens HCB101 via InxMed Pact, Testing 2 Agents Beyond Gastric Cancer

   2 outlets · first: Pr Newswire Clinical trial Mostly press releases

   Machine summary In a preclinical MOU, HanchorBio will evaluate its CD47/SIRPα asset HCB101 alongside InxMed’s ifebemtinib and OMTX705.

   1. HanchorBio and InxMed signed an MOU for preclinical/translational combination research of HCB101 with IN10018/ifebemtinib (Phase III FAK inhibitor) and OMTX705 (FAP-targeted ADC), with no upfront payments or binding clinical commitments disclosed.
   2. HCB101 is a SIRPα-Fc fusion protein targeting CD47/SIRPα, currently in clinical development with gastric cancer as the anchor indication, also being explored for head and neck and colorectal cancers.
   3. InxMed's ifebemtinib has moved into a Phase III trial located in China for platinum-resistant recurrent ovarian cancer, and the FDA has given it Fast Track designation.
   4. HanchorBio is a clinical-stage company listed on the Taiwan Stock Exchange (TWSE: 7827), and the MOU was executed through its subsidiary FBD Biologics Limited.

   Reported by Pr Newswire and manilatimes.net.

   • FBD Biologics Limited
   • HCB101
   • IN10018/ifebemtinib
   • HanchorBio, Inc.
   • OMTX705

2. 0405:30 UTC

   Phase 1 Trial Launches for Ac-225 PSMA Therapy: 1st Patient Dosed in mCRPC

   2 outlets · first: finanznachrichten.de Clinical trial Mostly press releases

   Machine summary Blue Earth Therapeutics doses first patient in Phase 1 trial of actinium-225 rhPSMA-10.1 for mCRPC, aiming to assess safety and inform dose selection. The trial leverages PSMA targeting with high-energy alpha particles to kill cancer cells.

   1. First patient dosed in Phase 1 trial (NCT07414940) evaluating Actinium (225Ac) rhPSMA‑10.1 Injection in metastatic castration‑resistant prostate cancer.
   2. Study sponsored by University College London (UCL), conducted at UCL Hospital, with funding and drug supply from Blue Earth Therapeutics.
   3. Trial will assess safety, tolerability, radiation dosimetry, and anti‑tumour activity to inform dose selection for subsequent research.
   4. Actinium-225 alpha particles deliver high‑energy, short‑range radiation causing irreparable DNA damage, aiming to limit collateral tissue exposure.
   5. This is Blue Earth’s second clinical radioligand candidate; its Lutetium (177Lu) rhPSMA‑10.1 program is already in Phase 2.

   Reported by finanznachrichten.de and Pr Newswire.

   • University College London
   • PSMA
   • Metastatic castration‑resistant prostate cancer (mCRPC)
   • Blue Earth Therapeutics
   • Actinium-225 (²²⁵Ac)
   • rhPSMA‑10.1 Injection

3. 0506:45 UTC

   Smith+Nephew announces German consensus on wound therapy

   2 outlets · first: finanznachrichten.de Pharma

   Machine summary Smith+Nephew said expert clinicians published consensus-based guidance for the use of single-use negative pressure wound therapy in closed surgical incisions, with practical recommendations for Germany in the journal Die Chirurgie. The company said the consensus was supported by Smith+Nephew, which manufactures the PICO 7 sNPWT system.

   1. According to Smith+Nephew, expert clinicians have published consensus-based guidance covering use of sNPWT (single-use negative pressure wound therapy) on closed surgical incisions, and the company announced this.
   2. The guidance was published in the journal Die Chirurgie, according to Smith+Nephew
   3. Smith+Nephew stated that it backed the German consensus, and it called itself a pioneer in sNPWT as well as the maker of the PICO 7 sNPWT system.
   4. Smith+Nephew said data identifies postoperative wound complications as a significant and systematic cost driver not consistently reimbursed within the DRG system
   5. According to Smith+Nephew, the PICO 7 is a portable, canister-free system for single-use negative pressure wound therapy, intended to provide -80 mmHg for a maximum of 7 days.

   Reported by finanznachrichten.de and manilatimes.net.

   • Germany
   • Smith & Nephew
   • Negative Pressure Wound Therapy (NPWT)
   • Die Chirurgie

Friday, July 10, 2026

1. 0612:45 UTC

   EPA's promised MAHA agenda has not materialized, activists say

   8 outlets · first: ABC News

   Reported by ABC News, Durango Herald, local10.com, baltimoresun.com, pressdemocrat.com, chicagotribune.com, isp.netscape.com and sun-sentinel.com.

2. 0712:32 UTC

   Coverage recordnynewscast.com: “Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative”

   3 outlets · first: nynewscast.com Clinical trial Mostly press releases

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by nynewscast.com, financialcontent.com and Globe Newswire.

   • Clearmind Medicine

Saturday, July 11, 2026

1. 0817:30 UTC

   Coverage recordnews.webindia123.com: “Sudan seeks more Indian investment in pharma, healthcare sector”

   2 outlets · first: news.webindia123.com Pharma

   Reports ran between 17:30 and 19:45 UTC on Jul 11.

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by news.webindia123.com and iraqsun.com (Big News Network).

   • Sudan

2. 0921:45 UTC

   Coverage recordindiagazette.com (Big News Network): “Sudan seeks more Indian investment in pharma, healthcare sector”

   2 outlets · first: indiagazette.com (Big News Network) Pharma

   Reports ran from 21:45 UTC on Jul 11 to 06:15 UTC on Jul 12.

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by indiagazette.com (Big News Network), zimbabwestar.com (Big News Network) and timesofoman.com.

   • Sudan

Sunday, July 12, 2026

1. 1012:00 UTC

   CaringAI presents cognitive screening research at AAIC 2026

   3 outlets · first: Rutland Herald Clinical trial

   Machine summary CaringAI announced that research on its telephone-based AI cognitive assessment platform, CaringAI Listen, was presented at the Alzheimer's Association International Conference 2026 in London.

   1. CaringAI said the research was presented at AAIC 2026 in London.
   2. According to CaringAI, the study evaluated clinician agreement with CaringAI Listen in real-world primary care.

   Reported by Rutland Herald, Times Argus and postregister.com.

   • CaringAI Listen
   • CaringAI

What kind of news was it?

1. Pharma 10
2. Clinical trial 7
3. Funding 3
4. Gene therapy 1